Burger JA. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep. 2014;9(1):44-49.Burger JA. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr. Hematol. Malig. Rep. 2014. p. 44-49....
5. Cool, Allison, et al. "BTK inhibitors: past, present, and future." Trends in Pharmacological Sciences (2024). 6. Stanchina, Michele D., et al. "Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lympho...
Clinical trials with other BTK inhibitors in B cell malignancies Sunesis的Vecabrutinib(SNS-062), ArQule公司的ARQ 531等非可逆的BTK抑制剂可以有效克服Ibrutinib耐药突变,最近开始进入人体临床研究,旨在克服Ibrutinib的半胱氨酸突变引起的耐药性。 靶向BTK的联合用药 BTK在经典的B细胞信号传导中起关键的作用。这包...
2. 信达生物官网 3. 礼来官网 4. 行业深度报告 BTK 抑制剂问世开启靶向治疗,新型疗法突破耐药难题, 平安证券 5. Cool, Allison, et al. "BTK inhibitors: past, present, and future." Trends in Pharmacological Sciences (2024). 6. Stanchina, Michele D., et al. "Navigating the changing landscape o...
Bruton's Tyrosine Kinase (BTK) Inhibitors in Clinical Trials BTK is a cytoplasmic, non-receptor tyrosine kinase that transmits signals from a variety of cell-surface molecules, including the B-cell receptor (BCR) and... Burger,Jan A. - 《Current Hematologic Malignancy Reports》 被引量: 123发...
In chronic lymphocytic leukemia (CLL), BTK inhibitors as monotherapy and in combination have expanded the armamentarium in both the frontline and relapsed/refractory settings, said Alexey V. Danilov, MD, PhD. Most recently, the BTK inhibitor acalabrutinib (Calquence) received FDA approval for the...
1. E. Wang et al., Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors. N. Engl. J. Med. 386,735-743 (2022). 2. Seymour et al. First Results from a Phase 1, First-in-Human Study of the Bruto...
5. Cool, Allison, et al. "BTK inhibitors: past, present, and future." Trends in Pharmacological Sciences (2024). 6. Stanchina, Michele D., et al. "Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia." Nature Reviews Clinical Onc...
Clinical trials with other BTK inhibitors in B cell malignancies Sunesis的Vecabrutinib(SNS-062), ArQule公司的ARQ 531等非可逆的BTK抑制剂可以有效克服Ibrutinib耐药突变,最近开始进入人体临床研究,旨在克服Ibrutinib的半胱氨酸突变引起的耐药性。 靶向BTK的联合用药 ...
5. Cool, Allison, et al. "BTK inhibitors: past, present, and future." Trends in Pharmacological Sciences (2024). 6. Stanchina, Michele D., et al. "Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia." Nature Reviews Clinical Onc...